MX2011010647A - Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos. - Google Patents
Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos.Info
- Publication number
- MX2011010647A MX2011010647A MX2011010647A MX2011010647A MX2011010647A MX 2011010647 A MX2011010647 A MX 2011010647A MX 2011010647 A MX2011010647 A MX 2011010647A MX 2011010647 A MX2011010647 A MX 2011010647A MX 2011010647 A MX2011010647 A MX 2011010647A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- aryl
- deuterium
- optionally
- optionally substituted
- Prior art date
Links
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical class OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052805 deuterium Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 239000011737 fluorine Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 abstract 1
- -1 arylcarboxylate Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La invención se refiere a un compuesto representado por la fórmula I o una sal farmacéuticamente aceptable del mismo. En la fórmula, R1 y R2 representan independientemente un hidrógeno, un deuterio, un arilo, un heteroarilo, un alquilo de C1-C8 eventualmente substituido por uno o varios sustituyentes representados independientemente por R3, R3 que representa un arilo, un heteroarilo, uno o varios átomos de flúor, un alquilo de C1-C6 que contiene uno o varios átomos de flúor, un alquilo de C1-C6 que contiene uno o varios átomos de deuterio, un alquilo de C1-C6 que contiene un hidroxi, el arilo y el heteroarilo que son eventualmente sustituidos por uno o varios átomos de halógeno, un alcoxi fluorado, un alquilo fluorado, un sulfonilo, uno o varios átomos de deuterio, un alquilo de C1-6, un alcoxi de C1-6, un nitrilo, o R3 representa un alquilo de C1-6 eventualmente sustituido por uno o varios de los grupos siguientes: COOR4, OCQR4, CONR5R6, NR5COR6, CR4; R4 que representa un alquilo de C1-10 eventualmente sustituido por uno o varios átomos de flúor, un átomo de deuterio, un alcoxi, un arilcarboxilato, un carboxilato de alquilo; R5 y R6 se seleccionan independientemente entre un hidrogeno y un alquilo, o forman junto con un núcleo de carbono que tiene 4 a 8 miembros; o R1 y R2 forman un núcleo de carbono dotado con 3 a 10 miembros que comprenden eventualmente O o N, y son eventualmente sustituidos por un arilo o un alquilo de C1-10, un heteroarilo eventualmente sustituido por R3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16722409P | 2009-04-07 | 2009-04-07 | |
| US17195609P | 2009-04-23 | 2009-04-23 | |
| PCT/SE2010/050375 WO2010117323A1 (en) | 2009-04-07 | 2010-04-06 | Method and apparatus for producing heat energy and carbon dioxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011010647A true MX2011010647A (es) | 2012-02-21 |
Family
ID=42934883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011010647A MX2011010647A (es) | 2009-04-07 | 2010-04-06 | Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8415378B2 (es) |
| EP (1) | EP2417131A4 (es) |
| JP (1) | JP5711723B2 (es) |
| KR (1) | KR101675607B1 (es) |
| CN (1) | CN102459246B (es) |
| AR (1) | AR076219A1 (es) |
| AU (1) | AU2010235236B2 (es) |
| BR (1) | BRPI1013984A2 (es) |
| CA (1) | CA2757879C (es) |
| CO (1) | CO6440580A2 (es) |
| CU (1) | CU20110190A7 (es) |
| EA (1) | EA020825B1 (es) |
| EC (1) | ECSP11011385A (es) |
| IL (1) | IL215336A0 (es) |
| MX (1) | MX2011010647A (es) |
| NI (1) | NI201100181A (es) |
| SG (1) | SG174463A1 (es) |
| TW (1) | TW201040166A (es) |
| UY (1) | UY32543A (es) |
| WO (1) | WO2010117323A1 (es) |
| ZA (1) | ZA201108119B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009279787B2 (en) | 2008-08-04 | 2014-05-29 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| NZ601547A (en) | 2010-01-25 | 2014-04-30 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CN103827095A (zh) | 2011-08-30 | 2014-05-28 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 |
| PH12017502049A1 (en) | 2011-08-30 | 2018-08-29 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9073881B2 (en) | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| CN102977040B (zh) * | 2012-11-20 | 2015-06-03 | 浙江工业大学 | 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法 |
| CN102977050B (zh) * | 2012-11-20 | 2015-04-22 | 浙江工业大学 | 一种2-苯并噻唑二甲缩醛和2-苯并噻唑甲醛的合成方法 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| PE20170770A1 (es) | 2014-07-17 | 2017-07-04 | Chdi Foundation Inc | Metodos y composiciones para tratar trastornos relacionados con vih |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10118930B2 (en) | 2014-11-03 | 2018-11-06 | Bayer Pharma Aktiengesellschaft | Piperidinylpyrazolopyrimidinones and their use |
| CA2967268A1 (en) * | 2014-12-19 | 2016-06-23 | Emeriti Pharma Ab | 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CN104725300A (zh) * | 2015-02-28 | 2015-06-24 | 宁波九胜创新医药科技有限公司 | 一种1-(6-甲基吡啶-3-基)-2-(4-甲磺酰基苯基)乙酮的制备方法 |
| WO2016173948A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones as fibrinolysis inhibitors |
| CN107459514B (zh) * | 2016-06-06 | 2020-10-23 | 南开大学 | 一类手性哌啶衍生物及其制备方法和用途 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CN107857725A (zh) * | 2017-12-19 | 2018-03-30 | 苏州艾缇克药物化学有限公司 | 一种2‑氨基吡啶‑4‑甲醇的合成方法 |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20230142746A (ko) * | 2021-02-05 | 2023-10-11 | 시노허브 파마슈티컬 씨오., 엘티디 | 플라스민 억제제, 이의 제조 방법 및 이의 용도 |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI962184L (fi) | 1993-11-24 | 1996-05-23 | Du Pont Merck Pharma | Uusia isoksatsoliini- ja isoksatsolifibrinogeenireseptoriantagonisteja |
| WO2000029406A2 (en) * | 1998-11-18 | 2000-05-25 | Du Pont Pharmaceuticals Company | Novel isoxazoline fibrinogen receptor antagonists |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| NZ543287A (en) * | 2003-04-15 | 2008-08-29 | Merck & Co Inc | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors |
| US7598243B2 (en) * | 2003-04-17 | 2009-10-06 | Merck & Co., Inc. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| CN101328173B (zh) * | 2008-07-31 | 2010-12-15 | 石药集团欧意药业有限公司 | 一种制备6-氟-3-(4-哌啶基)-1,2-苯并异噁唑盐酸盐的方法 |
-
2010
- 2010-04-06 EP EP10761933.0A patent/EP2417131A4/en not_active Withdrawn
- 2010-04-06 US US12/755,010 patent/US8415378B2/en not_active Expired - Fee Related
- 2010-04-06 AU AU2010235236A patent/AU2010235236B2/en not_active Ceased
- 2010-04-06 SG SG2011067568A patent/SG174463A1/en unknown
- 2010-04-06 CN CN201080025847.5A patent/CN102459246B/zh not_active Expired - Fee Related
- 2010-04-06 CA CA2757879A patent/CA2757879C/en not_active Expired - Fee Related
- 2010-04-06 JP JP2012504655A patent/JP5711723B2/ja not_active Expired - Fee Related
- 2010-04-06 KR KR1020117026407A patent/KR101675607B1/ko not_active Expired - Fee Related
- 2010-04-06 EA EA201190237A patent/EA020825B1/ru not_active IP Right Cessation
- 2010-04-06 TW TW099110636A patent/TW201040166A/zh unknown
- 2010-04-06 MX MX2011010647A patent/MX2011010647A/es active IP Right Grant
- 2010-04-06 WO PCT/SE2010/050375 patent/WO2010117323A1/en not_active Ceased
- 2010-04-06 BR BRPI1013984A patent/BRPI1013984A2/pt not_active Application Discontinuation
- 2010-04-06 UY UY0001032543A patent/UY32543A/es not_active Application Discontinuation
- 2010-04-07 AR ARP100101162A patent/AR076219A1/es unknown
-
2011
- 2011-09-22 IL IL215336A patent/IL215336A0/en unknown
- 2011-10-06 CO CO11132448A patent/CO6440580A2/es not_active Application Discontinuation
- 2011-10-07 CU CU20110190A patent/CU20110190A7/es unknown
- 2011-10-07 NI NI201100181A patent/NI201100181A/es unknown
- 2011-10-07 EC EC2011011385A patent/ECSP11011385A/es unknown
- 2011-11-04 ZA ZA2011/08119A patent/ZA201108119B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5711723B2 (ja) | 2015-05-07 |
| BRPI1013984A2 (pt) | 2018-06-19 |
| ZA201108119B (en) | 2012-07-25 |
| NI201100181A (es) | 2012-06-14 |
| IL215336A0 (en) | 2011-12-29 |
| WO2010117323A1 (en) | 2010-10-14 |
| AR076219A1 (es) | 2011-05-26 |
| JP2012522836A (ja) | 2012-09-27 |
| KR101675607B1 (ko) | 2016-11-11 |
| CU20110190A7 (es) | 2012-02-15 |
| AU2010235236A1 (en) | 2011-10-20 |
| CA2757879C (en) | 2017-06-06 |
| US8415378B2 (en) | 2013-04-09 |
| UY32543A (es) | 2010-11-30 |
| EA020825B1 (ru) | 2015-02-27 |
| US20100261755A1 (en) | 2010-10-14 |
| SG174463A1 (en) | 2011-10-28 |
| KR20120034611A (ko) | 2012-04-12 |
| CA2757879A1 (en) | 2010-10-14 |
| TW201040166A (en) | 2010-11-16 |
| EP2417131A1 (en) | 2012-02-15 |
| AU2010235236B2 (en) | 2013-10-24 |
| CO6440580A2 (es) | 2012-05-15 |
| EA201190237A1 (ru) | 2012-04-30 |
| ECSP11011385A (es) | 2011-11-30 |
| CN102459246B (zh) | 2014-05-07 |
| CN102459246A (zh) | 2012-05-16 |
| WO2010117323A8 (en) | 2010-11-18 |
| EP2417131A4 (en) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011010647A (es) | Analogos de isoxasol-3 (2h)-ona como agentes terapeuticos. | |
| CO6220952A2 (es) | Nuevos derivados de 3-([1,2,4]triazolo[4,3-a]piridin-7-il)benzamida | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| MA38540B1 (fr) | Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6 | |
| NZ592827A (en) | Methods of preparing quinoline derivatives | |
| EA201170096A1 (ru) | Замещенные производные пиримидона | |
| EA201070872A1 (ru) | Производные азабициклических карбоксамидов, их получение и их применение в терапии | |
| PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
| WO2005028445A3 (en) | Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain | |
| TNSN08372A1 (en) | Heterocyclic amides for use as pharmaceuticals | |
| EA201791781A1 (ru) | Производные замещенного моно- и полиазанафталина и их применение | |
| EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
| MX2014004144A (es) | Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5). | |
| MX2010013939A (es) | Derivados de n-oxido pirazina sustituidos. | |
| AR087494A1 (es) | Derivados de isoxazolina como compuestos insecticidas | |
| MX2014006992A (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| PH12015500400A1 (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders | |
| EA201690408A1 (ru) | Производные этинила | |
| EA201391538A1 (ru) | Производные пиразолидин-3-она | |
| TW200604185A (en) | Chemical compounds | |
| MA32527B1 (fr) | Derives 6-heterocyclique -imidazo[1,2-a]pyrroine-2-carboxamides, leur preparation et leur application en therapeutique | |
| EA201300100A2 (ru) | Способ ферментативного синтеза (7s)-3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбоновой кислоты или ее сложных эфиров и применение для синтеза ивабрадина и его соли | |
| EA201100360A1 (ru) | Производные аминоспиртов, предназначенные для лечения демиелинизирующих периферических невропатий | |
| PL400292A1 (pl) | Pochodne pirazolo[4,3-d]pirymidyno-7(6H)-onu jako inhibitory PDE9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |